Scholarlink

<p>Limited research has been conducted on the prevalence and factors associated with extended drug-susceptible tuberculosis (TB) treatment. A retrospective study enrolled drug-susceptible TB patients (January 2018 to December 2020) from a hospital’s registry to analyze prevalence, reasons, and factors for extended treatment (≥ 9 months) compared with standard course. Analyzing 221&#xa0;TB patients, 80 patients received extended treatment. The extended group showed higher hepatitis B infection rates (12.5% vs. 5%, <i>p</i> = 0.043), recent cancer treatment (18.8% vs. 8.5%, <i>p</i> = 0.025), more adverse drug events (ADEs) (grade 3 or more severe ADEs 27.5% vs. 11.3%, <i>p</i> = 0.003), and treatment interruptions (46.3% vs. 18.4%, <i>p</i> &lt; 0.001). Logistic regression highlighted hepatitis B infection (AOR 3.10, <i>p</i> = 0.039), recent cancer treatment (AOR 3.09, <i>p</i> = 0.013), and post-treatment elevated aminotransferase (AOR 2.40, <i>p</i> = 0.014) as independent factors for extended treatment. Extended anti-TB treatment affects 28.7% of patients, with host characteristics and adverse drug effects playing a role in treatment duration. Integrating these factors into treatment strategies is vital for optimal patient care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis – a real-world experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月27日

查看全文
  • Chih-Yu Liu,
  • Rou-Tsern Chen,
  • Chin-Chung Shu,
  • Shu-Yung Lin

摘要

Limited research has been conducted on the prevalence and factors associated with extended drug-susceptible tuberculosis (TB) treatment. A retrospective study enrolled drug-susceptible TB patients (January 2018 to December 2020) from a hospital’s registry to analyze prevalence, reasons, and factors for extended treatment (≥ 9 months) compared with standard course. Analyzing 221 TB patients, 80 patients received extended treatment. The extended group showed higher hepatitis B infection rates (12.5% vs. 5%, p = 0.043), recent cancer treatment (18.8% vs. 8.5%, p = 0.025), more adverse drug events (ADEs) (grade 3 or more severe ADEs 27.5% vs. 11.3%, p = 0.003), and treatment interruptions (46.3% vs. 18.4%, p < 0.001). Logistic regression highlighted hepatitis B infection (AOR 3.10, p = 0.039), recent cancer treatment (AOR 3.09, p = 0.013), and post-treatment elevated aminotransferase (AOR 2.40, p = 0.014) as independent factors for extended treatment. Extended anti-TB treatment affects 28.7% of patients, with host characteristics and adverse drug effects playing a role in treatment duration. Integrating these factors into treatment strategies is vital for optimal patient care.